Headspace App

Results in LGS

Hayden, living life with LGS


Significant seizure reduction is worth fighting for

Families affected by LGS fight for better seizure control each and every day.

FINTEPLA provides results that are worth fighting for: significant seizure reduction across seizure types commonly experienced in LGS.

 
In a 14-week clinical study, FINTEPLA reduced monthly drop seizures by 24% compared with 9% for patients taking placebo

In the LGS clinical study, the FINTEPLA 0.7 mg/kg/day was the only dose to significant reduce monthly drop seizures.

Seizure reduction was maintained throughout the 14-week study period.

People in the study experienced a reduction in drop seizures* across a variety of seizure types.

46% reduction in GTC,† 31% reduction in tonic, 34% reduction in atonic, and 47% reduction in tonic-atonic seizures 46% reduction in GTC,† 31% reduction in tonic, 34% reduction in atonic, and 47% reduction in tonic-atonic seizures

*Seizures that were confirmed to result in drops.
†Generalized tonic-clonic.

FINTEPLA is available only through the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS), which requires monitoring for potential side effects, such as problems with the heart valves or high blood pressure in the arteries of the lungs. The FINTEPLA REMS was created with your loved one’s safety in mind. It requires that your loved one have regular heart checkups (echocardiograms) to help manage potential safety concerns. 
Please see Important Safety Information.

FINTEPLA was studied in patients experiencing serious and hard-to-treat seizures

This study compared monthly drop seizure reduction between 2 different doses of FINTEPLA (0.7 mg/kg/day and 0.2 mg/kg/day) and placebo over a 14-week treatment period.

263 patients with LGS enrolled in the clinical study. It compared monthly drop seizure reduction between 2 different doses of FINTEPLA (0.7 mg/kg/day and 0.2 mg/kg/day) and placebo over a 14-week treatment period.

All patients in the clinical study were between ages 2 and 35 (with 29% of patients being 18 years old or older).

Before the Study

Patients had been treated with an average of 7 other antiseizure medicines.

Patients were having at least 8—and an average of 194—seizures that resulted in drops or falls or injuries per month.

Some patients had interventional procedures, such as vagal nerve stimulation or a corpus callosotomy.

During the Study

All patients were being treated with 1 to 4 other antiseizure medicines or treatments. The most common medicines were clobazam, lamotrigine, and valproate. Treatment plans included the ketogenic diet.

Patients were randomly placed into 1 of 3 groups where they took 0.7 mg/kg/day of FINTEPLA, 0.2 mg/kg/day of FINTEPLA, or placebo. All patients added FINTEPLA or placebo to their current antiseizure treatment plans.

In the clinical study, 0.7 mg/kg/day was the only dose of FINTEPLA to significantly reduce monthly drop seizures.

Clinical Global Impression–Improvement (CGI-I)

CGI-I, a 7-point scale where 1 is very much improved, 4 is no change, and 7 is very much worse

At the end of the 14-week study of FINTEPLA for LGS, each patient’s healthcare provider and parent or caregiver compared the patient’s overall functioning to how it was before starting treatment with FINTEPLA. Both groups ranked overall functioning using CGI-I, a 7-point scale where 1 is Very Much Improved and 7 is Very Much Worse.

More healthcare providers and caregivers saw an improvement‡ on the CGI-I scale for patients treated with FINTEPLA than patients treated with placebo.

‡A score of 1-3 means improvement; a score of 4 means no change; a score of 5-7 means worsening.

Results worth fighting for:

Now, after being on FINTEPLA for 3 years, Devon can go 2, 3, sometimes 4 weeks without any kind of seizure activity.

— Tracy, Devon’s mom

Long-term results

94% of patients continued with FINTEPLA and participated in a long-term open-label extension study†

Throughout this 15-month, long-term, open-label extension study, most patients maintained the seizure reduction they experienced in the clinical study.

In this open-label extension study:

50% of patients experienced at least 7 drop seizure-free days in a row25% of patients experienced at least 17 drop seizure-free days in a row

Patients added FINTEPLA (up to 0.7 mg/kg/day) to their current antiseizure treatment plans.
Since this was an open-label, flexible-dose study, no conclusions of efficacy should be made based on these results. Results may vary. An open-label study means patients knew they were being treated with FINTEPLA and not a placebo.

Family MomentsAre worth fighting for

Hear from real families who fought for better seizure control and found the results they were hoping for with FINTEPLA.

Watch family stories
 

Considering FINTEPLA for LGS?

Download a discussion guide designed to help you navigate these important conversations with your healthcare provider.

Get the guide

FINTEPLA CLINICAL NURSE EDUCATORS (CNEs) ARE HERE TO HELP

If you have questions about FINTEPLA, talk with a FINTEPLA CNE who can help you make informed decisions.

Call a CNE

Indication

Read more +

  • FINTEPLA is a prescription medicine used to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older.
  • It is not known if FINTEPLA is safe and effective in children less than 2 years of age.

Important Safety Information

FINTEPLA can cause serious side effects, including:

  1. 1.Problems with the valves in the heart (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension) have been associated with fenfluramine, the active ingredient in FINTEPLA. Your healthcare provider will do a test called an echocardiogram to check your heart and to evaluate for high blood pressure in the arteries of the lungs before you start taking FINTEPLA, again every 6 months during treatment, and one time 3 to 6 months after you take your last dose of FINTEPLA.

    Call your healthcare provider right away if you develop any of these signs and symptoms of heart or lung problems during treatment with FINTEPLA:

    • shortness of breath
    • tiredness or weakness, especially with increased activity
    • lightheadedness or fainting
    • swollen ankles or feet
    • chest pain
    • sensations of a rapid, fluttering heartbeat (palpitations)
    • irregular pulse
    • bluish color of your lips and skin (cyanosis)

    Because of the risk of heart valve problems (valvular heart disease) and high blood pressure in arteries of lungs (pulmonary arterial hypertension), FINTEPLA is only available through a restricted program called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) Program. Before you or your child receives FINTEPLA, your healthcare provider or pharmacist will make sure you understand how to take FINTEPLA safely. If you have any questions about FINTEPLA, ask your healthcare provider, visit www.FinteplaREMS.com, or call 1-877-964-3649.

  2. 2. Decreased appetite and decreased weight. Decreased appetite and decreased weight are both serious and common side effects of FINTEPLA in people with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS).

    • Your weight should be checked regularly during your treatment with FINTEPLA.
    • Your healthcare provider may need to make changes to your FINTEPLA dose if your weight decreases. In some cases, FINTEPLA may need to be stopped.

  3. 3. Sleepiness, sedation, and lack of energy (lethargy). These are both serious and common side effects of FINTEPLA in people with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS). Taking FINTEPLA with central nervous system (CNS) depressants, including alcohol, may increase sleepiness. Do not drive, operate heavy machinery, or do other dangerous activities until you know how FINTEPLA affects you.

  4. 4. Like all other antiepileptic drugs, FINTEPLA may cause suicidal thoughts or actions in a very small number of people (about 1 in 500).

    Call your healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:

    • thoughts about suicide or dying
    • trouble sleeping (insomnia)
    • attempts to commit suicide
    • new or worse irritability
    • new or worse depression
    • acting aggressive, being angry or violent
    • new or worse anxiety
    • acting on dangerous impulses
    • feeling agitated or restless
    • an extreme increase in activity and talking (mania)
    • panic attacks
    • other unusual changes in behavior or mood

    How can I watch for early symptoms of suicidal thoughts and actions?

    • Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.
    • Keep all follow-up visits with your healthcare provider as scheduled.

    Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

  5. 5. Do not stop taking FINTEPLA without first talking to your healthcare provider. Stopping a seizure medicine such as FINTEPLA can suddenly cause you to have seizures more often or seizures that do not stop (status epilepticus).

    Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

    Do not take FINTEPLA if you:

    • are allergic to fenfluramine or any of the ingredients in FINTEPLA. See below for a complete list of ingredients in FINTEPLA.
    • are taking or have stopped taking medicines called monoamine oxidase inhibitors (MAOIs) in the last 14 days. This may cause a serious or life-threatening problem called serotonin syndrome. If you are not sure whether or not you are taking one of these medicines, contact your healthcare provider.

    Before taking FINTEPLA, tell your healthcare provider about all of your medical conditions, including if you:

    • have heart problems
    • have or have had weight loss
    • have or have had depression, mood problems, or suicidal thoughts or behavior
    • have kidney problems
    • have liver problems
    • are pregnant or plan to become pregnant. Tell your healthcare provider right away if you become pregnant while taking FINTEPLA. You and your healthcare provider will decide if you should take FINTEPLA while you are pregnant.
      • If you become pregnant while taking FINTEPLA, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334 or go to www.aedpregnancyregistry.org. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.
    • are breastfeeding or plan to breastfeed. It is not known if FINTEPLA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking FINTEPLA.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

    How should I take FINTEPLA?

    • Read the Instructions for Use for information on the right way to use FINTEPLA.
    • Take FINTEPLA exactly as your healthcare provider tells you to take it.
    • Your healthcare provider will tell you how much FINTEPLA to take and when to take it.
    • FINTEPLA may be taken with or without food.
    • Measure your dose of FINTEPLA using the dosing syringe that is provided by the pharmacy. Do not use a household teaspoon or tablespoon.
    • FINTEPLA can be given through gastric and nasogastric feeding tubes.

    What should I avoid while taking FINTEPLA?

    • Do not drive, operate heavy machinery, or do other dangerous activities until you know how FINTEPLA affects you. FINTEPLA may cause you to feel sleepy.

    What are the possible side effects of FINTEPLA?

    FINTEPLA may cause serious side effects, including:

    • See “FINTEPLA can cause serious side effects” above
      • Serotonin syndrome. Serotonin syndrome is a life-threatening problem that can happen in people taking FINTEPLA, especially if FINTEPLA is taken with certain other medicines including: anti-depressant medicines called SSRIs, SNRIs, TCAs, and MAOIs; tryptophan; lithium; antipsychotics; St. John’s Wort; dextromethorphan; tramadol. Call your healthcare provider right away if you have any of the following symptoms of serotonin syndrome:
        • mental status changes such as seeing things that are not there (hallucinations), agitation, or coma
        • changes in blood pressure
        • tight muscles
        • fast heartbeat
        • nausea, vomiting, diarrhea
        • high body temperature
        • trouble walking
      • High blood pressure (hypertension). Hypertension is both a serious and common side effect. FINTEPLA can cause your blood pressure to increase even if you have never had high blood pressure before. Your healthcare provider will check your blood pressure while you are taking FINTEPLA.
      • Increased pressure in your eyes (glaucoma). Symptoms of glaucoma may include:
        • red eyes
        • seeing halos or bright colors around lights
        • nausea or vomiting
        • decreased vision
        • eye pain or discomfort
        • blurred vision

    If you have any of these symptoms, call your healthcare provider right away.

    • The most common side effects of FINTEPLA when used to treat Dravet syndrome (DS) include:
      • decreased appetite
      • diarrhea
      • low energy
      • respiratory infection
      • decreased weight
      • fever
      • constipation
      • abnormal echocardiogram
      • sleepiness
      • problems with movement, balance, and walking
      • increased drooling
      • increased blood pressure
      • vomiting
      • falls
      • seizures that do not stop
      • weakness
    • The most common side effects of FINTEPLA when used to treat Lennox-Gastaut syndrome (LGS) include:
      • diarrhea
      • tiredness
      • vomiting
      • sleepiness
      • decreased appetite

These are not all the possible side effects of FINTEPLA. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Keep FINTEPLA and all medicines out of the reach of children.

General information about the safe and effective use of FINTEPLA.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use FINTEPLA for a condition for which it was not prescribed. Do not give FINTEPLA to other people, even if they have the same symptoms that you have. It may harm them.

What are the ingredients in FINTEPLA?

Active ingredient: fenfluramine hydrochloride

Inactive ingredients:

  • cherry flavor
  • citric acid
  • ethylparaben
  • hydroxyethylcellulose
  • methylparaben
  • potassium citrate
  • sucralose
  • and water.

FINTEPLA contains no ingredient made from gluten-containing grain (wheat, barley, or rye) and contains not more than 0.1% of carbohydrates, which is from the cherry flavoring.

Please see full Prescribing Information, including Medication Guide, for additional Important Safety Information on FINTEPLA.